Dr. Reddy’s Laboratories has informed that, on November 22, 2022, the company and Dr. Reddy’s Laboratories, Inc. (a wholly owned subsidiary of the Company) had been named as defendants, along with Celgene, Bristol Myers Squibb, and several other generic pharmaceutical companies, in a complaint that asserts claims under federal and state antitrust law and other state laws alleging that defendants improperly restrained competition and maintained a shared monopoly in the sale of brand and generic Revlimid in the United States. On December 22, 2022 and December 27, 2022, the plaintiffs voluntarily dismissed Dr. Reddy’s Laboratories and Dr. Reddy’s Laboratories, Inc., respectively, from the case. All claims against the Company in the litigation have now been dismissed.
The above information is a part of company’s filings submitted to BSE.
